Skip to main
TMDX

TMDX Stock Forecast & Price Target

TMDX Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 33%
Buy 33%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

TransMedics Group is well positioned for continued growth with its proprietary Organ Care System (OCS) technology and solid financial guidance for the next fiscal year, including expected revenue growth of 20-25% and gross margins of 60%. The company also reported strong Q4 results, beating key metrics and indicating potential for even stronger growth in the future. Key points from the call highlight potential future revenue drivers, including expansion of the OCS platform and investments in the OUS franchise. With a strong track record and a potential to beat consensus estimates, TransMedics Group presents a compelling investment opportunity.

Bears say

TransMedics Group is facing challenges in conducting clinical trials as the maker of the Styrofoam coolers used for comparison is worried about the impact on their business; however, management remains confident in the trials enrolling successfully. The October 2025 SRTR data reflects positive transplant volumes and we anticipate continued growth in the coming months; therefore, we have raised our price target to $166.

TMDX has been analyzed by 9 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 33% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Transmedics Group Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Transmedics Group Inc (TMDX) Forecast

Analysts have given TMDX a Buy based on their latest research and market trends.

According to 9 analysts, TMDX has a Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $148.22, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $148.22, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Transmedics Group Inc (TMDX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.